Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!)
    Chat 3/28/2025

    At a glance
    In this treatment experience post, the primary subjects mentioned are
    πŸ’Š Dutasteride (oral) stopped for a few months
    πŸ’Š Minoxidil (oral) stopped for a few months
    β€’ RU58841
    the tone is 😞 negative.

    Other terms

    The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
    View this post in the Community β†’

    Similar Community Posts Join

    5 / 143 results

      community Oral minoxidil - how important is dermastamping?

      in Microneedling 3 days ago
      A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hair follicle stimulation, with some expressing surprise at the high minoxidil dosage.

      community Veradermics VDPHL01: why isn’t anyone talking about it?

      in Treatment  43 upvotes 10 months ago
      Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

      community PP405 Update and My Take on Pelage

      in Research/Science  85 upvotes 2 weeks ago
      Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

    Related Research

    6 / 1000+ results